A breakthrough in pancreatic cancer treatment: evaluation of a new dual therapy

Pancreatic ductal adenocarcinoma (PDA) is one of the leading causes of cancer-related mortality. This malignancy is characterized by its resistance to conventional treatments and immune checkpoint inhibitors (ICIs). Due to its late detection, poor long-term survival rate, and rising incidence, identifying new therapeutic approaches remains a critical priority.

In this context, this study investigates the combination of entinostat—an inhibitor of histone deacetylases (HDACi)—and nivolumab—a PD-1 inhibitor—as a dual therapy designed to remodel the tumor microenvironment and stimulate immune responses in patients with advanced PDA.

An effective dual therapy for advanced PDA?

Twenty-seven patients with advanced PDA, refractory to standard chemotherapies, were included in this study. The treatment protocol involved weekly administration of entinostat for 14 days, followed by a combination therapy with nivolumab administered biweekly. The effectiveness of this protocol was assessed using RECIST 1.1 criteria, focusing on the objective response rate (ORR).

The dual therapy demonstrated a partial response rate of 11%, with a median duration of response of 10.2 months. The median progression-free survival (PFS) was 1.89 months, while the median overall survival (OS) was estimated at 2.73 months. However, 63% of patients experienced grade ≥3 adverse events, primarily linked to entinostat.

Biologically, the treatment promoted dendritic cell maturation and activated inflammatory pathways, enabling durable responses in a minority of patients.

Promising biological insights, but challenges remain

This study highlights the potential of the entinostat-nivolumab combination as an innovative approach to treating advanced PDA. The observed immunological mechanisms provide promising avenues for the development of new combinatory strategies. However, the modest clinical outcomes and frequent adverse events indicate that this dual therapy requires further optimization and investigation to extend its benefits to a broader patient population.